Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Creative Commons License

Keskin D., Sadri S., Eskazan A. E.

Drug design, development and therapy, cilt.10, ss.3355-3361, 2016 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10
  • Basım Tarihi: 2016
  • Doi Numarası: 10.2147/dddt.s85050
  • Dergi Adı: Drug design, development and therapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.3355-3361
  • Anahtar Kelimeler: chronic myeloid leukemia, comorbidity, dasatinib, mutation, tyrosine kinase inhibitor, TYROSINE-KINASE INHIBITORS, CHRONIC MYELOGENOUS LEUKEMIA, LARGE GRANULAR LYMPHOCYTOSIS, PULMONARY ARTERIAL-HYPERTENSION, DURABLE CYTOGENETIC RESPONSES, 2-YEAR FOLLOW-UP, CHRONIC-PHASE, BCR-ABL, PLEURAL EFFUSION, 100 MG
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet